Travel Vaccine Business Grows 22%

As the world reopened following the recent pandemic, international travelers sought innovative vaccines to protect themselves from infectious diseases.
For example, Bavarian Nordic A/S announced results for 2024 today, stating that its travel health business demonstrated strong growth of 22% in vaccine sales. Rabipur®/RabAvert® (rabies) and Encepur® drove this performance.
Paul Chaplin, President and CEO of Bavarian Nordic, released a press release on February 3, 2025, stating, "Our (vaccine) portfolio continues to grow, and we are truly excited to launch our chikungunya vaccine for travelers over 12 years old in Europe and the U.S. later this year."
"We are also continuing to expand our partnerships to improve access to critical vaccines for vulnerable populations around the globe."
Research reveals that about 1.4 billion air passengers traveled in 2024, a number that may increase by 9.9% annually through 2028.
Furthermore, last-minute travelers deferred about 18% of protective vaccines because of insufficient time before departure.
Our Trust Standards: Medical Advisory Committee